EU Orphan Law Under Attack Over ‘Flawed Incentives’
BMJ Claims Firms Made ‘Billions’ In Profits
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
You may also be interested in...
Participants at a workshop on the EU’s proposed Pharmaceutical Strategy discussed affordability and drug shortages and called for more urgency on the draft HTA regulation.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.